Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2011

Phase III Levomilnacipran Study Fails to Meet Primary Endpoint in Major Depressive Disorder

  • Partners Forest Laboratories and Pierre Fabre Medicament said top-line results from a Phase III trial with levomilnacipran for the treatment of major depressive disorder (MDD) suggest the study has not met its primary endpoint. The data is in contrast to a previously completed, placebo-controlled Phase II trial, which showed that treatment using levomilnacipran led to statistically significant improvements in the Montgomery-Asberg Depression Rating Scale-Clinician-Rated (MADRS-CR).

    The newly reported Phase III study took the form of a placebo-controlled, flexible-dose trial involving 362 adult MDD patients. After a one-week run-in period patients were randomized to receive either 40-120 mg of levomilnacipran once daily, or placebo, for eight weeks plus an additional two-week down-taper period. Topline results found that although levomilnacipran consistently led to improvements in MADRS-CR scores over the course of the trial, the differences between drug treatment and placebo were not statistically significant.

    Two additional placebo-controlled Phase III studies with levomilnacipran in patients with MDD are ongoing. Results are expected during the second half of 2011.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »